Question Bank › The feared thing keeps not happening

The feared thing keeps not happening

The feared thing keeps not happening: management confronts a specific live worry with current evidence running against i

Calls Tested
994
Answered YES
93
Hit Rate
9.4%
rare by design

Hesai Group (HSAI) — this company's answers

NO on the Q4 2023 call 2024-03-12 D
The model's full reasoning — Q4 2023 call → NO我们根据提供的财报电话会议记录,判断是否存在一个具体的负面担忧,以及管理层是否用已观察到的证据进行反驳。 首先,寻找具体的担忧。在电话会议中,分析师和公司管理层都提到了几个担忧: 1. 与U.S. DoD的争议(1260H清单),可能影响与美国OEM的合作。管理层承认这有负面影响,但表示正在处理,并强调公司不是军事公司。这算是一个具体的担忧,但管理层的回应主要是澄清和诉讼,没有提供已观察到的业务证据来反驳担忧(比如美国OEM订单仍在增长等)。实际上,管理层承认“it has impacted us in a negative way”,所以担忧是存在的,但证据显示担忧正在实现,而不是反驳。 2. 关于订单预测的波动性,分析师问及如何应对订单变化,管理层提到有折扣和产能,但这是关于未来应对,不是已观察到的证据。 3. 关于ASP下降,管理层承认ASP下降接近20%,但成本下降更快,所以毛利率保持。这算是对担忧的回应,但证据是成本控制,不是需求或客户行为。 4. 关于robotaxi业务放缓,管理层明确说“a significant slowdown in our robotaxi business”,并提到某个大客户暂停交付。这确实是一个担忧,但管理层承认了,并说这不会影响毛利率目标,但并没有用已观察到的证据反驳,而是说ADAS增长弥补。实际上,担忧是存在的,且正在发生。 5. 关于全球OEM合作,管理层提到有2个全球OEM项目,但SOP在2025年,不是当前证据。 关键点:是否有分析师反复追问的担忧?分析师Cindy问及DoD争议,管理层承认有影响。分析师问及订单波动,管理层说已打折。分析师问及ASP,管理层承认下降。分析师问及robotaxi,管理层承认放缓。这些担忧都是具体的,但管理层的回应大多是承认或解释,而不是用已观察到的业务证据反驳。 然而,有一个可能的担忧:市场担心LiDAR需求会因价格竞争而下降,但管理层指出LiDAR正成为标准配置,渗透到更低价车型,并提到Li Auto将LiDAR作为标准配置,增加了订单。这算是对“需求担忧”的反驳,但这是基于订单和合作,是已观察到的吗?管理层说“Li Auto may ADAS standard equipment on their popular L7 and L8 Pro versions, immediately added hundreds of thousands of LiDAR units to Hesai's growing order book.” 这是已发生的合作,是具体证据。另外,管理层提到“we have won over 60 ADAS series production EV models from 16 major OEMs”,这也是已发生的。 但问题要求的是“SPECIFIC NEGATIVE OUTCOME”和“management push back by pointing to CURRENT, ALREADY-OBSERVED evidence”。我们需要找到一个明确的担忧,并且管理层用已观察到的证据反驳。 在电话会议中,有一个明显的担忧:市场担心LiDAR需求会因价格竞争而下降,或者担心公司增长不可持续。但管理层用订单增长、新合作等反驳。然而,这些反驳更多是展望,而不是针对某个具体担忧。 另一个担忧是robotaxi业务放缓,管理层承认了,没有反驳。 或许担忧是“竞争加剧导致市场份额流失”,但管理层没有直接回应。 再仔细看,分析师Tina问及“shipment forecast”和“2 million cumulative”,管理层说这是保守估计,并提到LiDAR成为标准配置,这是基于现有订单。但这不是针对一个具体负面担忧。 我认为最接近的是:市场担心LiDAR需求会因价格战而萎缩,但管理层指出LiDAR正成为安全标配,渗透到低价车型,并且有具体合作(如Li Auto、Great Wall、Leapmotor)和订单增长。这算是对“需求担忧”的反驳,但担忧是否被明确命名?管理层在回答中提到了“mass market opportunity”,但并没有说“有人担心需求下降”。 在电话会议中,分析师没有直接问“需求是否会下降”,而是问订单波动、ASP等。管理层在回答中提到了“snowball effect”和“demand for LiDAR”,但这是主动陈述。 或许担忧是“与DoD争议影响美国业务”,管理层承认有影响,没有反驳。 因此,我认为没有明确的一个担忧被管理层用已观察到的证据反驳。管理层承认了robotaxi放缓,承认了DoD影响,承认了ASP下降,但用成本控制等回应,而不是用业务证据反驳。 所以答案应为NO。

← Back to the full HSAI analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, is there a SPECIFIC NEGATIVE OUTCOME that investors, analysts, or the market have plainly been worried will happen to THIS company — a worry that is live on this call, evident either because analysts keep probing it or because management itself names it as a concern others hold — AND does management push back on that worry by pointing to CURRENT, ALREADY-OBSERVED evidence from the business showing that the feared outcome is, so far, NOT materializing? Answer YES when BOTH halves come through in the transcript as one coherent dynamic, in whatever form fits the business: (1) A NAMED, COMPANY-SPECIFIC FEAR THAT IS LIVE NOW. The worry is concrete and attached to this company — for example: that demand will fall off after an unusually strong stretch; that a major customer, contract, or partner will shrink, leave, or not renew; that a competitor, new technology, or cheaper alternative will take the company's business; that a key product, franchise, or pricing level is about to erode; that recent growth is a one-time bulge that will reverse; or another identifiable adverse outcome the market has been bracing for. The fear must be visible on the call itself — analysts returning to it in their questions, or management acknowledging in its own words that this is what people are worried about — not merely a generic risk factor or ordinary caution. (2) MANAGEMENT ANSWERS WITH OBSERVED BEHAVIOR, NOT REASSURANCE. Management responds by citing things that have ALREADY HAPPENED or are happening now — customers renewing, reordering, or expanding when they were expected to leave; demand holding or growing through the period when a drop-off was predicted; the threatened product, customer, or pricing actually performing in the recent period; competitive losses that have not shown up in real accounts; the feared cliff period arriving and being cleared — described with enough concrete substance (who, what, how much, or compared to when) that the rebuttal rests on evidence from the business rather than on confidence, promises, arguments about why the fear is illogical, or projections that the future will be fine. Answer NO if no specific company-attached worry is visible on the call — a routinely healthy company fielding ordinary questions is not this. Answer NO if the fear is visible but management's response is mainly reassurance, optimism, plans, or forecasts without already-observed evidence against it. Answer NO if the evidence shows the feared outcome IS materializing and management is excusing, minimizing, or promising to fix it. Answer NO if the worry is only broad macro or industry-wide gloom with nothing specific to this company's own business. Answer NO if management concedes the fear is valid and pivots to a different story instead of countering it. Answer NO if the counter-evidence is only a single vague assertion (such as 'demand remains strong') with no concrete grounding in what has actually occurred. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
AVTR Avantor, Inc. Q2 2024 2024-07-26 C+
IFS Intercorp Financial Services Inc. Q1 2024 2024-05-14 C+
AZEK The AZEK Company Inc. Q2 2024 2024-05-08 B+
GL Globe Life Inc. Q1 2024 2024-04-23 F
MNKD MannKind Corporation Q4 2023 2024-02-27 C
NICE NICE Ltd. Q4 2023 2024-02-22 B+
TYGO Tigo Energy, Inc. Q4 2023 2024-02-14 F
MET MetLife, Inc. Q4 2023 2024-02-01 B+
BBVA Banco Bilbao Vizcaya Argentaria, S.A. Q4 2023 2024-01-30 B+
TBLA Taboola.com Ltd. Q3 2023 2023-11-08 B+
GMED Globus Medical, Inc. Q3 2023 2023-11-07 B
DASH DoorDash, Inc. Q3 2023 2023-11-01 C+
MAC The Macerich Company Q3 2023 2023-10-31 D
LNTH Lantheus Holdings, Inc. Q2 2023 2023-08-03 C+
SITM SiTime Corporation Q2 2023 2023-08-02 C+
TREX Trex Company, Inc. Q2 2023 2023-07-31 B+
REYN Reynolds Consumer Products Inc. Q1 2023 2023-05-10 C
DOCN DigitalOcean Holdings, Inc. Q1 2023 2023-05-09 C+
ULCC Frontier Group Holdings, Inc. Q1 2023 2023-05-07 C+
AKR Acadia Realty Trust Q4 2022 2023-05-06 B+
BRX Brixmor Property Group Inc. Q1 2023 2023-05-02 A
EPR EPR Properties Q1 2023 2023-04-27 C+
MEDP Medpace Holdings, Inc. Q1 2023 2023-04-25 B+
DKS DICK'S Sporting Goods, Inc. Q4 2022 2023-03-07 B
CRBG Corebridge Financial, Inc. Q4 2022 2023-02-22 B
POOL Pool Corporation Q4 2022 2023-02-16 C+
ADPT Adaptive Biotechnologies Corporation Q4 2022 2023-02-14 C+
REGN Regeneron Pharmaceuticals, Inc. Q4 2022 2023-02-03 C
HBAN Huntington Bancshares Incorporated Q4 2022 2023-01-20 B
A Agilent Technologies, Inc. Q4 2022 2022-11-21 B+
PCTY Paylocity Holding Corporation Q1 2023 2022-11-05 A
TT Trane Technologies plc Q3 2022 2022-11-02 A
APOG Apogee Enterprises, Inc. Q2 2023 2022-09-20 A
CRL Charles River Laboratories International Q2 2022 2022-08-03 C
SGRY Surgery Partners, Inc. Q2 2022 2022-08-02 B+
ZBRA Zebra Technologies Corporation Q2 2022 2022-08-02 C+
LIN Linde plc Q2 2022 2022-07-28 B+
SHW The Sherwin-Williams Company Q2 2022 2022-07-27 D
JBHT J.B. Hunt Transport Services, Inc. Q2 2022 2022-07-19 C+
OGI OrganiGram Holdings Inc. Q3 2022 2022-07-14 B+
KFY Korn Ferry Q4 2022 2022-06-22 B
SE Sea Limited Q1 2022 2022-05-17 F
DCGO DocGo Inc. Q1 2022 2022-05-14 C
ZVIA Zevia PBC Q1 2022 2022-05-12 B
EGHT 8x8, Inc. Q4 2022 2022-05-10 C+
CCRN Cross Country Healthcare, Inc. Q1 2022 2022-05-04 B
ABNB Airbnb, Inc. Q1 2022 2022-05-03 B+
BXP Boston Properties, Inc. Q1 2022 2022-05-03 A
BSX Boston Scientific Corporation Q1 2022 2022-04-27 B
CCK Crown Holdings, Inc. Q1 2022 2022-04-26 C+
FR First Industrial Realty Trust, Inc. Q1 2022 2022-04-21 A
SDIG Stronghold Digital Mining, Inc. Q3 2021 2021-11-30 F
GFS GLOBALFOUNDRIES Inc. Q3 2021 2021-11-30 A
IPGP IPG Photonics Corporation Q3 2021 2021-11-02 C
HSY The Hershey Company Q3 2021 2021-10-28 C
PEP PepsiCo, Inc. Q3 2021 2021-10-05 B
GDS GDS Holdings Limited Q2 2021 2021-08-17 C+
PTVE Pactiv Evergreen Inc. Q2 2021 2021-08-08 C+
SPG Simon Property Group, Inc. Q2 2021 2021-08-02 B
GLW Corning Incorporated Q2 2021 2021-07-27 B+
DOV Dover Corporation Q2 2021 2021-07-20 B+
VLRS Controladora Vuela Compañía de Aviación, Q2 2021 2021-07-16 B+
MAR Marriott International, Inc. Q2 2018 2018-08-07 B
VALE Vale S.A. Q2 2018 2018-07-26 B
FICO Fair Isaac Corporation Q3 2018 2018-07-26 C+
ORAN Orange SA Q2 2018 2018-07-26 B
KIM Kimco Realty Corporation Q2 2018 2018-07-26 B+
TRUE TrueCar, Inc. Q1 2018 2018-05-08 C
TGNA TEGNA Inc. Q1 2018 2018-05-08 B+
CVS CVS Health Corporation Q1 2018 2018-05-02 B+
ALLY Ally Financial Inc. Q1 2018 2018-04-26 B+
MIDD The Middleby Corporation Q4 2017 2018-02-28 C
SBUX Starbucks Corporation Q1 2018 2018-01-26 C
AVT Avnet, Inc. Q2 2018 2018-01-25 B
GURE Gulf Resources, Inc. Q3 2017 2017-11-14 F
HOLX Hologic, Inc. Q4 2017 2017-11-08 D
MKTX MarketAxess Holdings Inc. Q3 2017 2017-10-25 C+
PII Polaris Inc. Q3 2017 2017-10-24 C+
LIND Lindblad Expeditions Holdings, Inc. Q2 2017 2017-08-06 C
BCRX BioCryst Pharmaceuticals, Inc. Q1 2017 2017-05-07 B
ICFI ICF International, Inc. Q1 2017 2017-05-06 B+
CGNT Cognyte Software Ltd. Q4 2016 2017-03-09 D
BDC Belden Inc. Q4 2016 2017-02-02 B
CAG Conagra Brands, Inc. Q2 2017 2016-12-22 C+
TGI Triumph Group, Inc. Q2 2017 2016-11-03 C+
SEM Select Medical Holdings Corporation Q1 2016 2016-05-06 C+
LPSN LivePerson, Inc. Q1 2016 2016-05-04 B
UVE Universal Insurance Holdings, Inc. Q1 2016 2016-05-03 C+
ESE ESCO Technologies Inc. Q2 2016 2016-05-03 A
VRTS Virtus Investment Partners, Inc. Q1 2016 2016-04-29 D
DD DuPont de Nemours, Inc. Q1 2016 2016-04-26 B+
BX Blackstone Inc. Q1 2016 2016-04-21 B
HPP Hudson Pacific Properties, Inc. Q4 2015 2016-02-25 C

How the model reasoned

TGI · Q2 2017 → YESThe question is: Is there a specific negative outcome that investors/analysts/market are worried about for THIS company, live on this call, and does management push back with CURRENT, ALREADY-OBSERVED...YES The specific, company-attached fear that is live on the call is that Triumph will continue to face large performance-related charges, cash burn on development programs, and failure to stabilize margins/cash flow despite the transformation (a worry analysts repeatedly probe via questions on the $80M risk, free-cash-use guidance, 747-8/C-17/G650 headwinds, and red programs). Management directly counters it by citing already-observed evidence: Q2 operating income of $70.
ULCC · Q1 2023 → YESThe question is: Is there a SPECIFIC NEGATIVE OUTCOME that investors/analysts/market have been worried about for THIS company, live on this call, AND does management push back with CURRENT, ALREADY-OB...YES The transcript shows a live, company-specific worry about pilot staffing shortages (tied to network changes and new contracts elsewhere) and customer churn/retention due to lower satisfaction scores. Management directly counters both with current evidence: pilot surplus and attrition on target for staffing, plus over 90% repeat business for retention.
HOLX · Q4 2017 → YESThe question is: Is there a SPECIFIC NEGATIVE OUTCOME that investors, analysts, or the market have plainly been worried will happen to THIS company, and does management push back on that worry by poin...YES The transcript shows a live, company-specific fear centered on Cynosure: investors and analysts are worried that the acquisition will not deliver sustainable growth, that recent sequential declines reflect a lasting salesforce collapse or competitive erosion, and that the business will continue underperforming expectations rather than turning around.

More from the question bank

Doors opening at the company's own gatesReporting the counterparty's growth as its oSecond proving already underwayNew normal declared and staffedBigger than they can carry aloneDemand arrived first, the company is growingAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.